Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.
Related Articles
A U.K. trade group is due to lift its suspension of Novo Nordisk, but critics cite a lack of transparency
The Association of British Pharmaceutical Industry says its audits of Novo Nordisk contain “company sensitive information… They are not intended to be public documents.”
Pharmalittle: We’re reading about HHS buyout offers, a Novo obesity trial, and more
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts
UnitedHealth’s deals and how big hospitals are faring
UnitedHealth’s deals, how big hospitals are faring, and more in this week’s Health Care Inc. newsletter.
Breaking the mold: Unconventional T cells in cancer therapy
Unconventional T cells, including invariant natural killer T (iNKT) cells, gamma delta (γδ) T cells, and mucosal-associated invariant T (MAIT) cells, play important roles in both innate…
2025 STAT Madness
2025 bracket Welcome to STAT Madness, a bracket-style contest to find the best innovation in science and medicine. Explore groundbreaking innovations from
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.
Mineralys Therapeutics stock soars on blood pressure drug data
Mineralys Therapeutics, a small drug developer, said its experimental drug significantly reduced blood pressure in two different studies, giving the medicine a path to market.
Mineralys Therapeutics stock soars on blood pressure drug data
Mineralys Therapeutics, a small drug developer, said its experimental drug significantly reduced blood pressure in two different studies, giving the medicine a path to market.
Pharmalittle: We’re reading about HHS buyout offers, a Novo obesity trial, and more
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts
Tariffs will make it even more expensive for Americans to eat healthy
Mexican and Canadian fruits and vegetables are ubiquitous in American grocery stores. Tariffs will put them further out of reach for many Americans.